A Federal Injunction Halts the 340B Rebate Pilot as of January 1, 2026—Here’s What Providers Need to Know and How to Prepare
As of January 1, 2026, HRSA has formally confirmed that its 340B Rebate Model Pilot Program is suspended. The update, quietly posted to HRSA’s website, follows a series of legal developments that now place the future of the rebate-based model firmly in question.
Source: HRSA Office of Pharmacy Affairs. “340B Model Contract Pharmacy Pilot Program.”
https://www.hrsa.gov/opa/340b-model-pilot-program
This confirmation marks a critical turning point for covered entities that had been closely monitoring the pilot—and for manufacturers that sought to replace up-front 340B discounts with a rebate mechanism.
What HRSA Confirmed on January 1, 2026
HRSA’s Office of Pharmacy Affairs (OPA) updated its website to state that implementation of the 340B Rebate Model Pilot Program is paused for all covered entity types.
According to HRSA, the pause is required under a December 29, 2025 preliminary injunction issued by the U.S. District Court for the District of Maine in American Hospital Association et al. v. Kennedy et al., No. 25-cv-600 (D. Me.).
The updated language makes clear that:
-
The rebate pilot is fully suspended as of noon on December 31, 2025
-
Manufacturers approved for the pilot may no longer use a rebate-based pricing model
-
Manufacturers must resume offering all covered outpatient drugs at the 340B ceiling price as an up-front discount, consistent with longstanding 340B requirements
-
HRSA will provide additional updates “as developments arise”
This effectively restores the status quo while litigation continues.
The Legal Context: Why the Pilot Was Blocked
On December 29, 2025, Chief Judge Lance E. Walker issued an injunction preventing HRSA from moving forward with the rebate pilot. Shortly thereafter:
-
The First Circuit Court of Appeals denied HRSA’s request for an administrative stay, meaning the pilot remains blocked for now
-
The court signaled it would expedite review to determine whether the injunction will remain in place longer term
While a final decision is still pending, the courts have made it clear that rebate-based substitution for statutory 340B discounts raises serious legal concerns.
Why This Matters for Covered Entities
Although the rebate pilot is paused, the broader implications are significant:
-
Federal courts are actively scrutinizing changes to how 340B pricing is delivered
-
Contract pharmacy arrangements remain under heightened attention
-
Covered entities should expect continued legal uncertainty and regulatory pressure
-
Manufacturers may pursue alternative strategies that still affect access and cash flow
In short, 340B program stability cannot rely on regulatory experiments alone. Covered entities must strengthen the fundamentals of their programs.
How American Exchange Helps Covered Entities Stay Resilient
In an environment where pilots are launched, challenged, and paused, covered entities need strategies that work regardless of regulatory volatility.
At American Exchange, we help providers reinforce their 340B programs by focusing on insured access, compliance, and sustainability through our Premium Insurance Assistance Program (PIAP).
PIAP Supports Your 340B Strategy By:
-
Identifying uninsured and Medicaid-disenrolled patients
-
Enrolling eligible individuals into ACA Marketplace plans
-
Administering monthly premium payments to prevent coverage gaps
-
Tracking eligibility, enrollment, and payments through our HIPAA-compliant IBMS platform
-
Increasing insured prescription volume, helping preserve 340B savings without reliance on unstable policy experiments
This approach aligns with HRSA’s long-term emphasis on transparency, eligibility, and patient access—regardless of how the courts rule on rebate models.
The Bottom Line
HRSA’s confirmation that the 340B Rebate Model Pilot is suspended as of January 1, 2026 underscores one reality: the 340B program remains legally complex and politically contested.
Covered entities that focus on insured patient access, compliant enrollment, and sustainable revenue models will be best positioned to weather ongoing uncertainty.
American Exchange is ready to help you do exactly that.
Schedule a strategy demo today
